Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.

被引：30

作者：

Iwata, Hiroji

Tamura, Kenji

Doi, Toshihiko

Tsurutani, Junji

Modi, Shanu

Park, Haeseong

Krop, Ian E.

Sagara, Yasuaki

Redfern, Charles H.

Murthy, Rashmi Krishna

Redman, Rebecca A.

Shitara, Kohei

Fujisaki, Yoshihiko

Sugihara, Masahiro

Zhang, Lin

Shahidi, Javad

Yver, Antoine

Takahashi, Shunji

机构：

[1] Aichi Canc Ctr, Nagoya, Aichi, Japan

[2] Natl Canc Ctr, Tokyo, Japan

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Kindai Univ, Fac Med, Osaka, Japan

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Washington Univ, Sch Med, St Louis, MO USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Social Med Corp Hakuaikai Sagara Hosp, Kagoshima, Japan

[9] Sharp Healthcare, San Diego, CA USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Louisville, Louisville, KY 40292 USA

[12] Natl Canc Ctr Hosp East, Chiba, Japan

[13] Daiichi Sankyo Co Ltd, Tokyo, Japan

[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[15] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.2501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2501

引用

页数：2